SC 13G/A: Cabaletta Bio, Inc.
Ticker: CABA · Form: SC 13G/A · Filed: Feb 14, 2024 · CIK: 1759138
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Cabaletta Bio, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 2,220 words · 9 min read · ~7 pages · Grade level 11.9 · Accepted 2024-02-14 16:21:51
Key Financial Figures
- $0.00001 — ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securiti
Filing Documents
- tm242424d12_sc13ga.htm (SC 13G/A) — 95KB
- 0001104659-24-023726.txt ( ) — 96KB
(a)
Item 1(a) Name of Issuer: Cabaletta Bio, Inc. (the "Issuer")
(b)
Item 1(b) Address of Issuer's Principal Executive Offices: 2929 Arch Street, Ste. 600 Philadelphia, PA 19104
(a)
Item 2(a) Name of Person Filing: This Amendment No. 1 is being filed jointly by the Reporting Persons.
(b)
Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690
(c)
Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.
(d)
Item 2(d) Title of Class of Securities: Common Stock, par value $0.00001 per share ("Common Stock").
(e)
Item 2(e) CUSIP Number: 12674W109 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) Investment company registered under section 8 of the Investment Company Act of 1940. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon conversion of non-voting common stock convertible at any time on a 1-for-1 basis without consideration into Common Stock ("Non-Voting Common Stock"), subject to the limitations on conversion described below. The information set forth below is based on 41,405,117 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023, plus 1,444,295 shares of Common Stock issuable upo